

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Location: Cisco Webex,
Meeting ID: 2496 256 1439
Password: JtxybE9Jp34

IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS

STATE OR LOCAL OFFICIALS CONTINUE TO IMPOSE OR RECOMMEND MEASURES TO PROMOTE SOCIAL DISTANCING. AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO “ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE” 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT aasejo@alamedaalliance.org. YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK: <https://alamedaalliance.webex.com/alamedaalliance> OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-408-418-9388. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MAY SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE OR PROVIDE COMMENT [DURING THE MEETING AT THE END OF EACH TOPIC](#).

PLEASE NOTE: THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. DURING EACH AGENDA ITEM, YOU WILL BE PROVIDED A REASONABLE AMOUNT OF TIME TO PROVIDE PUBLIC COMMENT. THE COMMITTEE WOULD APPRECIATE, HOWEVER, IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING.

AGENDA

ITEM VOTE	DESCRIPTION	TIME
I)	Call to order <i>Steve O’Brien, MD, Chief Medical Officer - Alameda Alliance</i> <ul style="list-style-type: none"> Agenda Overview 	2 min -
II)	Informational Updates <i>Steve O’Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> NCQA Survey DMHC Mental Health Audit CalAIM initiative MediCalRx 	15 min -

MCDAC Drug	Indication	MCDAC Drug Formulary Status	Action Based on - Safety, Efficacy, Essential Need, Misuse Potential, etc.	Previous MCAL Status
Balcofra (levonorgestrel and ethinyl estradiol) 0.10mg/0.02mg tablets	Female oral contraceptive	F-PA	Leave As Is	NF
Divigel (estradiol) 0.1% gel	Moderate to Severe Vasomotor Symptoms due to Menopause	F-PA	Leave As Is	F-PA
Myfembree (relugolix, estradiol and norethindrone) 40mg/1mg/0.5mg tablets	Heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women	F-PA	Leave As Is	NF
Tyrvaya (varenicline solution) nasal spray	Dry Eye Disease symptoms	F-PA	Leave As Is	NF

III) Pharmacy Utilization Reports (Quarter 1, 2022)

Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance

- Top 50 Drugs by Cost
- Top 50 PA Reviewed Drugs

2 min -

ADJOURN TO CLOSED SESSION (*Pursuant to California Government Code Title 5, §54954.5(h)*)

Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes

Estimated Date of Public Disclosure: 6/21/2022 (*formulary changes only; no trade secrets will be disclosed*).

IV) E-Voting Material/Consent Agenda

The following items have been sent to the voting committee for review via E-voting

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

Monographs/Class Reviews	Changes
Contraceptive Foams, Devices class	• No change
Potassium Supplements class review	• No change
Gaucher Disease class review	• No change
Sucraid monograph	• No change
Provenge monograph	• No change
Medication Request Guidelines	Changes
Criteria for long acting opioids	<ul style="list-style-type: none"> • Add generic Butrans, Conzip, and Ryzolt to policy for completeness • Remove Arymo from policy: obsolete • Change brand/generic status of Hysingla ER (hydrocodone) • Minor grammar and formatting changes
Criteria for short acting opioid containing products	• Minor grammar and formatting changes
Epidiolex (cannabidiol)	<ul style="list-style-type: none"> • Add weight requirement • Add clarifying language
Tiagabine (Gabitril)	<ul style="list-style-type: none"> • Update initial approval length to 6 months • Remove duplicative language

10 min E
V

Banzel	<ul style="list-style-type: none"> • Change brand/generic status
Topiramate (Topamax) sprinkles	<ul style="list-style-type: none"> • Change brand/generic status of Qudexy
Fenofibrates	<ul style="list-style-type: none"> • Add quantity limits notation • Remove Triglide: obsolete • Change brand/generic status of Antara
Specialty Biological Agents for Ankylosing Spondylitis	<ul style="list-style-type: none"> • Add Rinvoq to policy to align with new indication for AS
Non-formulary and prior authorization required oral liquid formulations	<ul style="list-style-type: none"> • Remove language referring to younger members. • Language updates for clarity
Hepatitis B Drugs	<ul style="list-style-type: none"> • Remove MCAL language
Movement Disorders	<ul style="list-style-type: none"> • Correct spelling
Palforzia	<ul style="list-style-type: none"> • Update indentation formatting • Correct spelling
Medications for Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy	<ul style="list-style-type: none"> • Align dosage formulations for generic Concerta • Add in step therapy language
Lupkynis	<ul style="list-style-type: none"> • No change
Vaginal Progesterone	<ul style="list-style-type: none"> • No change
Formulary, step therapy required *For drugs without specific criteria	<ul style="list-style-type: none"> • No change
Daliresp (roflumilast)	<ul style="list-style-type: none"> • No change
febuxostat (Uloric)	<ul style="list-style-type: none"> • No change
Aptiom (eslicarbazepine)	<ul style="list-style-type: none"> • No change
Lamotrigine ER	<ul style="list-style-type: none"> • No change
Levalbuterol (Xopenex/Xopenex HFA)	<ul style="list-style-type: none"> • No change
Lidocaine Patch	<ul style="list-style-type: none"> • No change
Nutritional formulas, infant formulas (STC C5F C5C)	<ul style="list-style-type: none"> • No change
Serotonin Receptor Agonists (Triptans)	<ul style="list-style-type: none"> • No change
Alprazolam (Xanax)	<ul style="list-style-type: none"> • No change
Rectiv (nitroglycerin) ointment	<ul style="list-style-type: none"> • No change
Physician Administered Drug (PAD) Guidelines	Changes
Healthcare professional (HCP) administered/IV Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)	<ul style="list-style-type: none"> • Add biosimilar statement • Add biosimilar suffixes • Remove Gilenya and Mayzent as pre-requisites

SMN2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy (SMA)	<ul style="list-style-type: none"> Update reauthorization wording to require positive clinical response
Veklury	<ul style="list-style-type: none"> Retire
B-Cell Maturation Antigen (BCMA) Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy	<ul style="list-style-type: none"> No change
Naglazyme	<ul style="list-style-type: none"> No change
Interim Formulary Updates	
<ul style="list-style-type: none"> See p. XX in packet 	
Pharmacy Policy & Procedure Updates	
<ul style="list-style-type: none"> RX-001 Pharmaceutical Operating Processes Summary 	<ul style="list-style-type: none"> Format edit
<ul style="list-style-type: none"> RX-002 PA Review Process 	<ul style="list-style-type: none"> Remove fertility and ED therapy from non-covered drug section Allow cosmetic and hair growth therapies for gender dysphoria, MH and SUD
<ul style="list-style-type: none"> RX-003 Exception Review Process 	<ul style="list-style-type: none"> Update IRR process language
<ul style="list-style-type: none"> RX-004 Formulary Management 	<ul style="list-style-type: none"> Remove fertility and ED therapy from non-covered drug section Allow cosmetic and hair growth therapies for gender dysphoria, MH and SUD
<ul style="list-style-type: none"> RX-005 P&T Committee Roles and Scope 	<ul style="list-style-type: none"> Format edits
<ul style="list-style-type: none"> RX-006 Pharmacy Services Staff Description 	<ul style="list-style-type: none"> No changes
<ul style="list-style-type: none"> RX-007 Pharmaceutical Patient Safety 	<ul style="list-style-type: none"> No changes (will need UM drug recall alignment shortly)
<ul style="list-style-type: none"> RX-008 PBM Delegated Audit Oversight 	<ul style="list-style-type: none"> Adopting PerformRx UM System Control policies
<ul style="list-style-type: none"> RX-009 Emergency Supply Provision 	<ul style="list-style-type: none"> No changes
<ul style="list-style-type: none"> RX-10 Drug Utilization Management 	<ul style="list-style-type: none"> Monthly DU encounter data from PBM just for Group Care (Section D)
<ul style="list-style-type: none"> RX-12 DU Policies – Pharmacy Portal DU Access 	<ul style="list-style-type: none"> Pharmacy Portal access process updates
ED Oversight	
<ul style="list-style-type: none"> No findings for Q2 2022 	
90 Day Maintenance List Updates	
<ul style="list-style-type: none"> No changes 	
P&T Meeting Minutes	
<ul style="list-style-type: none"> P&T Meeting Minutes Q1 March 15, 2022 	

V) New Business

- Helen Lee, PharmD, Pharmacist, Alameda Alliance*
Timothy Tong, PharmD, Pharmacist, Alameda Alliance
- AAHUM Medication PA List

VI) Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

1. DPP-4 Inhibitor class review
2. Atypical antipsychotics class review
3. Insomnia class review
4. Potassium Removing Agents class review
5. Ridaura monograph

VII) Medication Request Guidelines

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

1. Calcitonin Gene-Related Peptide (CGRP) Antagonists for Headache Prevention
2. Acute Migraine Treatments
3. Rapid-Acting Insulin
4. Pregabalin (Lyrica and Lyrica CR)
5. Ophthalmic Anti-inflammatory Immunomodulators
6. Carbamazepine – retire
7. Vimpat (Iacosamide) – retire
8. Modafinil and Armodafinil – retire
9. Sunosi, Wakix, Xyrem, and Xywav
10. Self-administered Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
11. Healthcare professional (HCP) administered/IV Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
12. Lipotropics
13. Hepatitis C Medications
14. Phosphate Binders
15. Hemlibra (emicizumab-kxwh)
16. Hereditary Angioedema (HAE)
17. Cholinesterase Inhibitors
18. Emflaza (deflazacort)
19. Vigabatrin (Sabril)

45 min **V**

VIII) Physician Administered Drug (PAD) Policies

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Calcitonin Gene-Related Peptide (CGRP) Antagonists for Headache Prevention
2. Anti-CD19 CAR-T Immunotherapies
3. Complement Inhibitors

10 min **V**

- IX) Informational Updates on New Developments in Pharmacy** 2 min
Natalee Felten, PharmD, Pharmacist, PerformRx
 - New Product Review

- X) Old Business** 2 min
Natalee Felten, PharmD, Pharmacist, PerformRx
 - None

RECONVENE IN OPEN SESSION

- XI) Public Comment**

- XII) Adjournment**
 - P&T Committee Member Forms

ACTION / FOLLOW-UP ITEMS

ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS

NEXT MEETING	2022 P&T MEETINGS
September 20th, 2022	December 20 th , 2022

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.